about
You are here
Cylene Pharmaceuticals is a clinical-stage, private company developing small molecule drugs against newly validated cancer targets.
Cylene’s leadership in exploiting CK2-dependent pathways enables the creation of first-in-class agents that serve as the drug of choice in rational drug combinations for improved treatment outcomes against many cancer indications. The Company’s POL l program delivers first-in-class targeted agents that act through the ideal non-genotoxic pathway for activating p53 to kill cancer cells. Cylene’s unique approach delivers innovative agents that enable pharmaceutical companies to expand their portfolios and extend the efficacy, lifecycle and reach of current cancer therapeutics.
Cylene’s approach to exploiting newly validated targets and key signaling pathways has created a pipeline of targeted cancer agents. These molecules, created in-house through Cylene’s unique mechanistic knowledge and chemistry expertise, are supported by an extensive intellectual property portfolio including 136 pending applications and 36 issued patents. The management team has the experience and talent to deliver these new agents as pharmaceutical drugs to patients and to the market. The company’s record of creativity, execution, frugality and pipeline creation have enabled Cylene to attract corporate and traditional venture capital investors alike. This solid foundation positions Cylene to deliver innovative drugs that will fulfill the unmet medical needs of cancer patients and their families.